Entyvio is an integrin receptor antagonist used to treat adult patients with ulcerative colitis and Crohn's disease. This product is manufactured by Takeda Pharmaceuticals, a Japanese pharmaceutical company. Entyvio is used for injection and supplied in a single-dose vial for injection.
What is it made of?
Entyvio 300mg contains vedolizumab, a humanized immunoglobulin G1 monoclonal antibody sourced from Chinese hamster ovary cells.
What are its uses?
Entyvio 300mg is indicated for adult patients with moderate to severe active ulcerative colitis. It is also indicated for adult patients with moderate to severe active Crohn's disease. This product helps patients who have responded poorly to tumor necrosis factor or other first line treatments.
How long do its effects last?
The duration of action of Entyvio 300mg is measured by its half-life. Pharmacokinetic analyses indicate that the serum half-life for this product is approximately 25 days.